The multinational has filed infringement proceedings and is seeking an injunction against the Indian rival at the Delhi High Court, trying to block the Bangalore-based biotechnology firm from launching a generic version of Galvus, also known as vildagliptin.
'We've got a huge track record and success in bringing several biosimilars to the market.'
'However, we have seen weakness in our active pharmaceutical ingredients business.'
Biotech major Biocon Limited announced on Wednesday a licensing agreement with multinational healthcare corporation Bayer HealthCare for exclusive marketing and trademark rights for INSUGEN, a recombinant human insulin, for the Chinese market.
Leading biotech firm, Biocon Ltd, on Tuesday said it would invest $10 million (about Rs 45 crore) in the next 12 months to expand its facilities.
Biotech firm Biocon will make equity investment in Vaccinex Inc. and said it has tied up with the US firm to discover and develop therapeutic antibody products for cancer, inflammation and autoimmune diseases.
Biotech major Biocon will file an application with the US Federal Drug Administration to begin clinical trials for oral insulin, which, it says, would be the world's first insulin that could be consumed orally.
Bangalore-based Biocon Ltd and a US biotech firm Nobex Corporation will jointly develop an oral insulin product for the treatment of diabetes.
Bangalore-based biotech company, Biocon is in the process of developing oral insulin for diabetes treatment.
Year 2008 results of India's largest drug maker, Ranbaxy Laboratories, and Wockhardt were also impacted by forex losses. Companies such as Aurobindo and Orchid are also expected to post forex losses, say analysts.
On course to become India's first biotech company to be listed on a stock exchange, Bangalore-based Biocon Ltd on Thursday kicked off a roadshow for its initial public offering that opens on March 11.
Indian firm to soon launch copycat of anti-breast-cancer drug.
Biocon, which sought to develop drugs for India and other emerging markets from home, is in a quandary.
Biocon has tied up with ICICI Prudential Life Insurance to market its insulin, Insugen. Accordingly, the company will offer insulin at a subsidised rate to all 'diabetic care' insurance policyholders of the insurance company.
Infosys will comply with whatever regulations and guidelines Karnataka comes up with, a top company official said on Thursday on the proposed reservations for locals in private firms in the state. Infosys employs over 3.15 lakh people at present across the globe. "We are planning to work with all the regulations of the state and central governments.
Biocon Ltd ill seek Drug Controller General of India's approval for its novel monoclonal antibody indicated towards the treatment of head and neck cancer, Biomab EGFR.
Leading bio-technology company Biocon Ltd on Monday said its research development partner, Nobex Corporation, has filed for bankruptcy in the US.
India's biotechnology major Biocon Ltd, is all set to make its way to Pakistan's pharmaceutical market by 2008 with its oncology drug BIOMAb EGFR.
Bangalore-based company aims to raise around Rs 300 crore
Nobex, after running out of money last year, had filed for bankruptcy.
Every year, BioSingapore receives nominations from biotechnology industry associations, industry peers, academics and institutions across Asia-Pacific for the most outstanding companies or individuals in various categories. The nominees are judged by a panel of distinguished leaders in the field.
Given the gestation period for regulatory clearances it is not possible to share any definite timelines.
New Zealand Prime Minister Helen Clarke on Monday said there were immense opportunities to enhance bilateral trade with India.
Biotechnology major Biocon India Ltd plans to invest over Rs 500 crore on its expansion plans over the next two years.
Indian biotech firm Biocon has been featured amongst the top 25 global biotehnology companies according to a report released by Med Ad News.
Biotech major Biocon, which has projected sales turnover of Rs 700-750 crore (Rs 7-7.5 billion) this year, on Friday said it will launch recombinant human insulin in two weeks.
Biotech firm Biocon India on Friday reported net profits of Rs 138.63 crore (Rs 1.39 billion) for the year 2003-04, a growth of 219 per cent over Rs 43.51 crore (Rs 435.1 million) recorded for the previous fiscal.
The initial public offering of the shares of Bangalore-based Biocon Ltd has received bids five times the one crore shares available for subscription within an hour of opening of the biding process on Thursday.
Biotechnology major Biocon has got the Drug and Controller General of India approval for marketing its BIOMAb EGFR in the Indian market. This is a proprietary product of Biocon, which will be used in treating head and neck cancers.
The company expects insulin, its other branded formulations and research services to drive growth.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances